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Report

Hypercholesterolemia is associated with hyperactive cardiac mTORC1
and mTORC2 signaling
Hilary P. Glazer,1,2 Robert M. Osipov,1 Richard T. Clements,1 Frank W. Sellke1,3 and Cesario Bianchi1,*
1Division of Cardiothoracic Surgery Research; Beth Israel Deaconess Medical Center & Harvard Medical School; Boston, MA USA; 2Washington University in St. Louis School
of Medicine; St. Louis, MO USA; 3Alpert Medical School of Brown University; Providence, RI USA

Abbreviations: mTOR, mammalian target of rapamycin; HC, hypercholesterolemic; NC, normocholesterolemic; S6K1, S6 kinase 1;
4EBP1, eukaryotic translation initiation factor 4E binding protein 1; S6, ribosomal protein S6; PKCα, protein kinase C alpha; I/R,
ischemia-reperfusion; mTORC1, mTOR complex 1; mTORC2, mTOR complex 2; mLST8, G protein β-subunit-like protein; PRAS40,
proline-rich Akt substrate of 40 kDa; AMPK, AMP-activated protein kinase; Rheb, ras homolog enriched in brain; REDD1, regulated
in development and DNA damage 1; HIF-1 responsive protein; SERCA2 ATPase, sarcoplasmic/endoplasmic reticulum calcium ATPase
2; LC3B, microtubule-associated protein 1 light chain 3B; HIF-1α, hypoxia-inducible factor 1α; MAP, mean arterial pressure
Key words: hyperlipidemia, nutrition, rapamycin, hypertrophy, ischemia, oxidative stress, autophagy, senescence, mitochondria, localization

Nutritional excess and hyperlipidemia increase the heart’s
susceptibility to ischemic injury. Mammalian target of rapamycin
(mTOR) controls the cellular response to nutritional status
and may play a role in ischemic injury. To explore the effect of
hypercholesterolemia on cardiac mTOR signaling, we assessed
mTOR signaling in hypercholesterolemic swine (HC) that are
also susceptible to increased cardiac ischemia-reperfusion injury.
Yucatan pigs were fed a high-fat/high-cholesterol diet for 4
weeks to induce hypercholesterolemia, and mTOR signaling
was measured by immunoblotting and immunofluorescence in
the non-ischemic left ventricular area. Total myocardial mTOR
and raptor levels were markedly increased in the HC group
compared to the normocholesterolemic group, and directly
correlated with serum cholesterol levels. mTOR exhibited
intense perinuclear staining in myocytes only in the HC group.
Hypercholesterolemia was associated with hyperactive signaling
upstream and downstream of both mTOR complexes, including
myocardial Akt, S6K1, 4EBP1, S6 and PKC-alpha, increased
levels of cardiac hypertrophy markers, and a trend toward lower
levels of myocardial autophagy. Hypercholesterolemia can now
be added to the growing list of conditions associated with aberrant mTOR signaling. Hypercholesterolemia produces a unique
profile of alterations in cardiac mTOR signaling, which is a
potential target in cardiac diseases associated with hypercholesterolemia and nutritional excess.
*Correspondence to: Cesario Bianchi; Beth Israel Deaconess Medical Center; 330
Brookline Ave., Dana 805C; Boston, MA 02215 USA; Tel.: 617.667.0342; Fax:
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Introduction
Hyperlipidemia is one of the most common risk factors for
coronary heart disease, and is associated with increased morbidity
and mortality from cardiac events and procedures.1,2 Major
studies have shown that diet, particularly those high in saturated
fat, also plays a fundamental role in cardiovascular risk.3 We
recently showed a 45% greater myocardial infarct after ischemiareperfusion (I/R) in hypercholesterolemic pigs fed a high-fat/
high-cholesterol diet for four weeks,4 which is much shorter than
the time needed to produce atherosclerosis.5 Fortunately, mortality
from cardiovascular disease has declined drastically in the last 50
years due to decreases in serum cholesterol and the modification
of other risk factors. Experts believe, however, that this trend has
slowed due to unhealthy eating patterns in the majority of the US
population, specifically with respect to the overconsumption of
energy-rich foods.6
Mammalian target of rapamycin (mTOR) plays a central role
in integrating the cell’s response to nutritional status, including
intracellular ATP, glucose and amino acid levels.7 Hyperactivation
of mTOR has been shown to increase most organs’ sensitivity to
oxidative stress.8 The etiology of many diseases associated with
aging has been attributed to increased oxidative stress and more
recently, to hyperactivation of mTOR through multiple mechanisms including nutrient excess.9 mTOR exists in mTOR complex
1 (mTORC1) with raptor and mTOR complex 2 (mTORC2)
with rictor. mTORC1 is activated by Akt and inhibited by AMPK,
and promotes protein synthesis and leads to cardiac hypertrophy
through its activation of S6K1 and S6, and inhibition of 4EBP1
and autophagy. mTORC2 activates Akt and PKCα, and may also
contribute to cardiac hypertrophy.10 While some studies have
shown that prior activation of Akt or S6K1 are important for
cell survival after I/R,11,12 others have suggested that rapamycin
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induces a metabolic state that protects cardiomyocytes from I/R
injury.10,13,14
The effect of hypercholesterolemia on mTOR signaling has
not been studied. We examined mTORC1 and 2 signaling in pigs
fed a high cholesterol diet for 4 weeks, in order to study the effect
of hypercholesterolemia on myocardial signaling independent of
secondary effects related to atherosclerosis and underlying ischemia.
Since hypercholesterolemia is likely produced through the complex
interplay of dietary and genetic factors, a large animal model was
used that may be more applicable to patients than traditional
rodent models.15 Here we describe that hyperactive myocardial
mTOR signaling is present in early hypercholesterolemia, and
implicate mTOR complex 1 and 2 signaling in altering myocardial
metabolism and susceptibility to ischemic injury.

Table 1

Lipid profile and body weight
NC

HC

p

Chol (mmol/L)

1.61 ± 0.27

13.8 ± 1.8

<0.01

LDL (mmol/L)

0.53 ± 0.05

5.46 ± 0.74

<0.01

HDL (mmol/L)

0.53 ± 0.06

1.81 ± 0.11

<0.01

TG (mmol/L)

0.30 ± 0.14

0.33 ± 0.03

0.051

Body Weight (kg)

22.4 ± 1.5

21.4 ± 0.9

0.54

Yucatan pigs were fed a normocholesterolemic (NC, n=6) or a high-fat/high-cholesterol diet (HC, n=7)
for 4 weeks. Serum total cholesterol (Chol), low-density lipoprotein (LDL), high-density lipoprotein
(HDL), triglycerides (TG) and body weight were measured. Values are expressed as mean ± SEM, with
corresponding p values.

Results
Biochemical parameters and body weight. The high-fat/
high-cholesterol diet induced significant elevations in serum total
cholesterol, LDL and HDL in the HC group (p < 0.01 for all;
Table 1). Triglycerides tended to be slightly higher in the HC
group (p = 0.051), and body weight was similar between groups.
Some pigs in the HC group displayed elevations in serum glucose
and insulin levels, but the differences were not significant, and
HOMA-IR, a measure of insulin resistance,16 tended to be higher
in the HC group (data not shown).
mTORC1 and 2 components. mTOR levels were increased
by about 3-fold in the HC group (p < 0.01), and raptor levels
were increased by more than 5-fold in the HC group (p < 0.01).
In contrast, levels of rictor and mLST8 were not significantly
different between groups (p = 0.4 and p = 0.8, respectively; Fig. 1).
mTOR and raptor levels exhibited strong direct correlations with
serum total cholesterol and HDL levels (Table 2; for correlation
plots see Suppl. Fig. 1). mTOR and raptor levels exhibited modest
and strong direct correlations with serum LDL, respectively.
There was no correlation between mTOR and raptor levels and
triglycerides or body weight. mTOR levels also showed a modest
correlation with insulin levels and HOMA-IR measurements,
while raptor levels showed no correlation with any measures of
insulin resistance (data not shown).
Signaling upstream of mTORC1. The phosphorylation of Akt
at Thr308, as measured by the ratio of phospho-to-total levels of
the protein, tended to be higher in HC group (p = 0.052; Fig. 2).
PRAS40 phosphorylation at Thr246 and mTOR phosphorylation
at Ser2448 were higher in the HC group (p < 0.05 and p < 0.01,
respectively). Total levels of Akt did not change (p = 0.6), while
total levels of PRAS40 tended to be slightly lower in the HC group
(p = 0.14). AMPKα phosphorylation at Thr172 was significantly
lower in the HC group (p < 0.01; Fig. 3), while levels of total
AMPKα were slightly higher in the HC group (p = 0.19). Levels
of Rheb were lower in the HC group (p < 0.05), while there was no
difference in REDD1 levels between the groups (p = 0.3).
mTORC1 activity. The phosphorylation of 4EBP1 at Thr37/46
and S6K1 at Thr389 was increased by more than 2-fold in the
HC group (p < 0.01 and p < 0.05, respectively; Fig. 4), and S6
phosphorylation at Ser240/244 was significantly higher in the HC
www.landesbioscience.com

Figure 1. Hypercholesterolemia is associated with significantly higher levels of cardiac mTOR and raptor. Representative western blots for mTOR,
raptor, rictor, mLST8 and α-tubulin in the left ventricle of hypercholesterolemic (HC) and normocholesterolemic (NC) pigs, and quantification of
the data. Bands were rearranged from the original gel for clarity of presentation. Densities were calculated relative to total Ponceau S staining. Data
are expressed as mean ± SEM. **p < 0.01 versus control.

group (p < 0.05). However, total levels of 4EBP1, S6K1 and S6
were unchanged (p = 0.4, 0.6 and 1, respectively).
mTORC2 activity. The phosphorylation of Akt at Ser473 was
significantly higher in the HC group (p < 0.05; Fig. 5). As measured
by a pan-PKC antibody with reactivity to Ser657 of PKCα, the phosphorylation of a PKC isoform at the same molecular weight as PKCα
was increased by more than 2-fold in the HC group (p < 0.01), and
levels of PKCα were also higher in the HC group (p < 0.01).
Immunolocalization of mTOR. Immunofluorescence studies
showed that mTOR was highly expressed in myocytes (Fig. 6),
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Table 2 Corrleation of lipid profile and body weight
with cardiac mTOR and raptor levels
	       mTOR		      raptor
r
p
r
Chol

0.57

LDL
HDL

p

<0.05

0.81

<0.001

0.53

0.06

0.77

<0.01

0.72

<0.01

0.81

<0.001

TG

0.24

0.41

0.33

0.27

Body Weight

0.08

0.79

0.05

0.86

Yucatan pigs were fed a normal or high-fat/high-cholesterol diet for 4 weeks. Left ventricular mTOR
and raptor levels were measured by immunoblotting. Serum total cholesterol (Chol), low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides (TG) and body weight were also measured.
Correlation (r) with corresponding p values are shown. For correlation plots, see Supplemental Figure 1.

(Suppl. Fig. 2A). mTOR did not co-localize in the HC group
with SERCA2 ATPase, a marker for the sarcoplasmic reticulum/
endoplasmic reticulum (Suppl. Fig. 2B).
Cardiac hypertrophy and autophagy. Total levels of β-actin,
troponin I, troponin T and SERCA2 ATPase were significantly
increased in the HC group (p < 0.05 for all; Fig. 7), while levels
of α-tubulin did not change (p = 0.7). The ratio of LC3B II/I also
tended to be lower in the HC group (p = 0.08).
Correlation between biochemical parameters and mTORC1
and 2 signaling. The ratio of phospho-to-total mTOR, 4EBP1,
Akt (Ser473) and total Rheb, PKCα, and SERCA2 ATPase
directly correlated with serum total cholesterol and LDL levels (See
Suppl. Table 1). The ratio of phospho-to-total AMPK inversely
correlated with serum total cholesterol, LDL and HDL. None
of the measured proteins or phosphorylated proteins exhibited a
correlation with triglycerides or body weight, except total PKCα
and troponin T, which directly correlated with triglycerides
(Suppl. Table 1).

Discussion

Figure 2. Hypercholesterolemia is associated with increased in cardiac Akt/mTOR signaling. Representative western blots for phospho-Akt
(Thr308), phospho-PRAS40 (Thr246), phospho-mTOR (Ser2448), and
total levels of Akt, PRAS40 and α-tubulin in the left ventricle of hypercholesterolemic (HC) and nomocholesterolemic (NC) pigs, and quantification
of the data. The phospho-mTOR blot corresponds to the total mTOR blot
shown in Figure 1. Bands were rearranged from the original gel for clarity of presentation. Densities were calculated relative to total Ponceau S
staining. Phosphorylation is presented as the phospho-to-total (p/t) ratio
of the protein. Data are expressed as mean ± SEM. *p < 0.05, **p <
0.01 versus control.

and could not be detected in other cardiac cell types, such as the
vascular endothelium or smooth muscle. Of the 3 animals examined from each group, all of the HC animals exhibited mTOR
staining in a punctate perinuclear distribution, whereas staining
for mTOR in the ND animals was diffusely cytoplasmic when
detectable. A similar cellular expression and distribution was seen
for phospho-S6K1 (data not shown). To confirm the specificity
of the mTOR antibody, we incubated the mTOR antibody
with a blocking peptide, and this eliminated mTOR staining
1740

Hypercholesterolemia is a major risk factor for coronary artery
disease, myocardial infarction and adverse outcomes after ischemic events.1 It is also associated with cardiac hypertrophy.17 We
demonstrate that early hypercholesterolemia in pigs increased total
levels of mTOR and raptor and activated mTORC1 signaling.
We show that mTORC2 signaling was activated since Akt and
PKCα signaling was increased. The hypercholesterolemic pigs also
showed higher levels of cardiac hypertrophy markers and a trend
toward inhibition of autophagy in the myocardium. These findings carry important implications for the role of mTOR in altering
cardiac metabolism in hypercholesterolemia, and may influence
the heart’s response to ischemia.
Hypercholesterolemia activated mTORC1 through several
mechanisms. Total levels of mTOR and raptor were increased and
directly correlated with serum cholesterol, indicating that may
be novel sensors to cholesterol levels. This occurred through an
as-yet-undefined mechanism since levels of FOXO1 and 4EBP1,
the only molecules known to regulate mTOR and raptor expression,18 were not changed (for FOXO1, see Suppl. Fig. 3A). In
addition, Akt and AMPK were upstream mediators leading to
activation of mTORC1. Akt was more phosphorylated on Thr308
and Ser473 in the HC group, and the mTORC1 inhibitor
PRAS40 was more phosphorylated on Thr246, indicating that
Akt contributed to mTOR activation via PRAS40 inhibition.19
The higher Ser2448 phosphorylation of mTOR also indicated that
mTORC1 was more activated by Akt in the HC group, although
S6K1 may also phosphorylate this site.20 AMPK, a key negative
regulator of mTORC1,7 was less active (less phosphorylated on
Thr172) in the HC group. Akt is sequentially activated, first by the
phosphorylation of Thr308 by PDK1 through PI3K signaling, and
then fully activated by mTORC2’s phosphorylation of Ser473.21
AMPK was likely inhibited by the high intracellular energy status
in the HC group, since fatty acids are a principal source of energy
to cardiomyocytes,22 and AMPK is inhibited by a high intracellular ATP/AMP ratio.23
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Figure 3. Effect of hypercholesterolemia on upstream modulators of
mTORC1 in the myocardium. Representative western blots for phosphoAMPKα (Thr172), AMPKα, Rheb, REDD1 and α-tubulin in the left ventricle
of hypercholesterolemic (HC) and normocholesterolemic (NC) pigs, and
quantification of the data. Bands were rearranged from the original gel for
clarity of presentation. Densities were calculated relative to total Ponceau
S staining. Phosphorylation is presented as the phospho-to-total (p/t) ratio
of the protein. Data are expressed as mean ± SEM. *p < 0.05, **p
<0.01 versus control.

Other upstream modulators of mTORC1 activity were also
altered in hypercholesterolemia, including Rheb, another nutrientstimulated activator of mTORC1,7 which was decreased in the
HC group. We also measured REDD1, which has been shown to
be induced by oxidative stress,24 but it showed no change in the
HC group, even though hypercholesterolemia is associated with
chronic oxidative stess.25 However, the major downstream targets
of mTORC1, 4EBP1 and S6K1, were hyperphosphorylated in
the HC group, indicating that mTORC1 was activated in the HC
group, likely due to both overexpression of mTOR and raptor
as well as stimulation of upstream signaling, including Akt and
AMPK. These sites (Thr36/47 on 4EBP1 and Thr389 on S6K1)
are classic measures of mTORC1 activity.26 We also observed
intense punctate perinuclear staining for mTOR in the HC group
compared to diffuse cytoplasmic staining when detectable in
the ND group. This is consistent with a similar shift in mTOR
staining observed in human cells in vitro when mTORC1 was
stimulated with amino acids, further suggesting that mTORC1
was activated in our model.27 Combined with the phospho-S6K1
immunostaining, this indicates that myocytes were the primary cell
type contributing to the hyperactive mTOR signaling in pigs fed a
high-fat/high-cholesterol diet. mTOR did not colocalize with the
sarcoplasmic reticulum/endoplasmic reticulum in the HC group,24
as it is believed to localize in some cell types,28 and whether any
organelles, such as mitochondria, are mainly affected by the
increased mTOR signaling/expression in hypercholesterolemia,
remains to be elucidated.
www.landesbioscience.com

Figure 4. Hypercholesterolemia is associated with increased phosphorylation of cardiac mTORC1 targets. Representative western blots for phospho4EBP1 (Thr37/46), phospho-S6K1 (Thr389), phospho-S6 (Ser240/244),
total levels of these proteins, and α-tubulin in the left ventricle of hypercholesterolemic (HC) and normocholesterolemic (NC) pigs, and quantification
of the data. Bands were rearranged from the original gel for clarity of
presentation. Densities were calculated relative to total Ponceau S staining. Phosphorylation is presented as the phospho-to-total (p/t) ratio of the
protein. Data are expressed as mean ± SEM. *p < 0.05, **p < 0.01
versus control.

We showed that hypercholesterolemia also activated myocardial
mTORC2. Total levels of rictor, a key component of mTORC2,29
and mLST8, a component common to both complexes, were not
altered in hypercholesterolemia. However, the phosphorylation
of Akt on Ser473 and PKCα on Ser657 were increased in the
HC group. These residues are the main sites phosphorylated by
mTORC2.21 mTORC2 also increases the stability of PKCα,30 and
total levels of PKCα were higher in the HC group. The activity of
mTORC2 may have been increased by the higher levels of mTOR
in hypercholesterolemia, or still unknown upstream mediators.
The major substrates of mTORC2 are Akt, which further activates
mTORC1, and PKCα, which affects microvascular function and
cardiac contractility.
Hypercholesterolemia and diets high in saturated fat are
independent risk factors for the development of left ventricular
hypertrophy, which heavily influences morbidity and mortality
from cardiovascular disease.17 The HC pigs displayed increased
markers of cardiac hypertrophy, which is significant in light of
the changes observed in mTOR signaling. mTORC1 regulates
the development of cardiac hypertrophy, primarily via promotion of protein synthesis in myocytes.31-33 We observed enhanced
phosphorylation of the ribosomal protein S6 in the HC group,
and when coupled with the increased phosphorylation of 4EBP1,
a translational inhibitor in its nonphosphorylated form, this
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Figure 5. Hypercholesterolemia is associated with increased phosphorylation of mTORC2 targets, and an increase in PKCα levels in the myocardium. Representative western blots for phospho-Akt (Ser473), phospho-PKC
(α, Ser657), total PKCα and α-tubulin in the left ventricle of hypercholesterolemic (HC) and normocholesterolemic (NC) pigs, and quantification of
the data. For total levels of Akt corresponding to the phospho-Akt (Ser473)
blot, see Figure 2. The phospho-PKC antibody was a phospho-pan PKC
antibody with reactivity to PKCα when phosphorylated at Ser657. This is
the thicker bottom band which overlapped with total PKCα. Bands were
rearranged from the original gel for clarity of presentation. Densities were
calculated relative to total Ponceau S staining. Phosphorylation is presented as the phospho-to-total (p/t) ratio of the protein. Data are expressed
as mean ± SEM. *p < 0.05, **p < 0.01 versus control.

indicates a trend toward increased protein synthesis in the
hypercholesterolemic myocardium. mTORC2 also plays a role
in cardiac hypertrophy,10 since it controls the actin cytoskeleton
and activates Akt and PKCα, which has been shown to maintain
contractile force by associating with troponin I in myocytes.34 The
effect of mTOR on the expression of both fetal and constitutive
hypertrophy genes is not well understood. However mTORC1
and 2 may contribute to the hypertrophic changes observed in the
hypercholesterolemic myocardium.
Hypercholesterolemia is a prevalent condition in patients with
ischemic heart disease, and influences outcomes after cardiac events
and procedures.1,2 Previous studies have focused on microvascular
and endothelial dysfunction as an explanation for hypercholesterolemia’s adverse cardiac effects.35,36 However, metabolic conditions
within myocytes influence the heart’s response to ischemic injury
and are altered by major cardiovascular risk factors.37,38 The hypercholesterolemic pigs in our study exhibited a 45% greater infarct
after ischemia-reperfusion than control pigs,4 after only four weeks
of feeding with a hypercholesterolemic diet that also activated
mTOR. Constitutive activation of mTOR has been shown both in
vitro and in vivo to induce necrosis, apoptosis and autophagic cell
death upon nutrient deprivation and hypoxia,39-43 and transgenic
mice with chronic activation of Akt displayed a larger infarct after
1742

cardiac I/R.44 Our study is the first to suggest that hyperactivation
of the mTOR pathway through dietary modifications in a large
animal model may sensitize the myocardium to I/R injury.
Hyperactive mTOR signaling may increase myocardial susceptibility to ischemic injury in several ways (Fig. 8). Decreasing
myocardial energy demand is a major strategy for reducing I/R
injury during acute myocardial infarction. mTORC1 instead
increases energy demand by activating translation and promoting
the development of a hypertrophic, hypercontractile phenotype.
In fact, inhibition of protein synthesis, in part through HIF-1αmediated downregulation of mTOR signaling,45 has been shown to
protect cells from hypoxia by reducing mTOR-mediated stimulation of translation. We observed a potential activation of translation
in both the ischemic and non-ischemic myocardial territories of
the HC group, including lower levels of HIF-1α, in conjunction
with higher S6K1 levels, which activates the ribosomal protein S6,
in the ischemic myocardial territory (Suppl. Fig. 3B). Similarly,
these HC pigs demonstrated hyperdynamic cardiac function
throughout the entire I/R event, including increased developed left
ventricular pressure, peak systolic function, and mean arterial pressure (MAP).4 On a molecular level, the activation of mTORC1
in the HC group also inhibited autophagy, an important cellular
process for degrading old organelles and proteins,46 as indicated by
the lower ratio of LC3B-II/I, a marker of autophagy.47 Combined
with increased protein synthesis, the activation of mTORC1 may
have led not only to a hypertrophic, hyperdynamic phenotype,
but also to the accumulation of misfolded proteins and damaged
mitochondria in the HC myocardium, increasing its susceptibility
to ischemia.48,49
mTORC2 may also play a role in ischemic injury through its
activation of PKCα and Akt. PKCα contributes to microvascular
dysfunction and I/R injury, especially in the setting of hypercholesterolemia.50,51 Akt may also contribute to the metabolic effects
of hypercholesterolemia on the myocardium, since it promotes the
intracellular transport of glucose and lipids52,53 and further activates mTORC1. We hypothesize that this coactivation of cardiac
mTORC1 and 2 perpetuates a hyperactive energy supply-anddemand cycle in the hypercholesterolemic myocardium, increasing
its susceptibility to the withdrawal of nutrients and oxygen upon
ischemia.
In conclusion, our study highlights a role for cardiac mTORC1
and 2 signaling in nutritional excess, hypercholesterolemia and
ischemic injury. It cannot (1) refute the possibility that hemodynamic stress, due to a high MAP or the acute I/R event also
activated mTOR signaling in the non-ischemic left ventricle;
nor (2) provide direct evidence that hypercholesterolemia specifically activates mTORC1 and 2 in myocytes. Instead, we used a
clinically-relevant porcine model of diet-induced hypercholesterolemia, which is known to produce multiple changes similar
to the metabolic syndrome in humans.15 These pigs had slight
hypertension, slight hypertriglyceridemia, and likely metabolic
changes in other organs that may have also contributed to the
alterations we observed in cardiac mTORC1 and 2 signaling. This
is a strength and not a weakness of our study since it implicates
hyperactive mTORC1 and 2 signaling in the cardiac pathologies
associated with a high-fat/high-cholesterol diet, and correlates
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Figure 6. Hypercholesterolemia is associated with perinuclear localization of mTOR within myocytes. Confocal microscopy of mTOR (yellow) in the left
ventricle of hypercholesterolemic (HC, a–c) and normocholesterolemic (NC, d–f) pigs. Perinuclear localization of mTOR is indicated with red arrowheads.
Sections were co-stained with 4',6'-diamidino-2-phenylindole (DAPI, blue). Representative images are shown for three pigs selected randomly from each
group. Scale bar represents 10 μm.

novel changes in mTOR and raptor expression with cholesterol
levels. Rapamycin, which dissociates mTOR from raptor and can
inhibit both mTORC1 and 2, is already being used clinically in
transplantation and drug-eluting stents. Given our findings, it
is worth examining the potential utility of rapamycin as well as
specific mTORC1 and 2 inhibitors in models of I/R, hypertrophy
and heart failure, particularly in the setting of hypercholesterolemia and other metabolic diseases.

Methods
Animals. At 20 weeks of age, seven intact male Yucatan miniswine were fed a normal diet (NC) consisting of standard Minipig
Breeder Diet (Purina, St. Louis, MO), while seven were fed a
hypercholesterolemic diet (HC) for 4 weeks that substituted 25%
of the ND with 17.2% coconut oil, 2.3% corn oil, 4% cholesterol
and 1.5% sodium cholate. Animals were housed individually and
provided with laboratory chow and water ad libitum. All experiments were approved by the Beth Israel Deaconess Medical Center
Animal Care and Use Committee and the Harvard Medical Area
Standing Committee on Animals. This investigation conforms with
the Guide for the Care and Use of Laboratory Animals published by
the US National Institutes of Health (NIH Publication No. 85-23,
revised 1996).
Pigs were fasted for 12 hours prior to harvesting the tissue
used in this study. They had undergone 1 hr. myocardial ischemia/2 hr. reperfusion of the left anterior descending coronary
artery for another study,4 and monastryl blue dye (Engelhard
Corp., Louisville, KY) was injected into the coronary arteries to
www.landesbioscience.com

demarcate the non-ischemic ventricular tissue before harvesting.
Only non-ischemic tissue was used in this study. Tissue was rapidly
frozen in liquid nitrogen and stored at -80°C for use in western
blotting. Tissue was fixed in 10% formaldehyde for 3 hours
followed by 20% sucrose overnight at 4°C, mounted in tissue
blocks with OCT (Sakura Finetek, Torrance, CA), and frozen at
-80°C for use in immunofluorescence studies.
Western blotting. Ventricular tissue from the non-ischemic
territory was homogenized in 25 mL RIPA buffer consisting of 50
mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% sodium
deoxycholate, 0.1% SDS (Boston Bioproducts, Worcester, MA),
phosphatase inhibitor cocktails I and II at 1:100 (Sigma, St. Louis,
MO), one-half tablet of Complete EDTA-free protease inhibitor
cocktail (Roche, Indianapolis, IN) and 64 mM NaF (Fisher
Scientific, Pittsburgh, PA). Protein concentration was quantified using the Micro BCA Protein Assay Kit (Pierce, Rockford,
Illinois) and equal amounts of protein (35 to 40 ug) were
subjected to SDS-PAGE on 4–20% polyacrylamide gels (Pierce,
Rockford, Illinois). Proteins were transferred to PVDF membranes
(Millipore, Bellerica, MA) at 40 V overnight. Membranes were
stained with Ponceau S to ensure equal protein transfer and separation. Membranes were blocked in 5% blotting-grade milk (Biorad,
Hercules, CA), washed in TBS with 0.05% Tween-20 (Boston
Bioproducts), followed by incubations in primary and secondary
antibodies and Supersignal West Pico Chemiluminescent Substrate
(Pierce) according to the manufacturers’ recommendation.
Optical density values were obtained from X-ray films using a
flat-bed scanner and ImageJ 1.4 software (National Institutes of
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Figure 7. Hypercholesterolemia is associated with increased levels
of hypertrophy-associated proteins, and a trend toward decreased
autophagy in the myocardium. Representative western blots for β-actin,
troponin I, troponin T, SERCA2 ATPase, α-tubulin, LC3B-I&II and GAPDH
as a loading control in the left ventricle of hypercholesterolemic (HC) and
normocholesterolemic (NC) pigs, and quantification of the data. Bands
were rearranged from the original gel for clarity of presentation. Densities
were calculated relative to total Ponceau S staining. The ratio of LC3B-II
to I (LC3B-II/Ir) was calculated by dividing the density of the bottom band
by that of the top on the LC3B blots. Data are expressed as mean ± SEM.
*p < 0.05 versus control.

Health, USA). All calculated densities were normalized to total
Ponceau S staining intensity. Protein phosphorylation was assessed
by dividing levels of the phosphorylated form of the protein by
levels of its total expression. Expression levels are presented in
arbitrary units as mean ± SEM. Samples were originally loaded in
a different order, and bands from X-ray films were rearranged in
the Figures for clarity of presentation.
Immunofluorescence. Three animals were analyzed randomly
from each group. Ten μm frozen sections from the non-ischemic
ventricular territory were washed in PBS for 5 min and treated
with 1% SDS (Boston Bioproducts) for 5 min. Sections were
washed 3 times before blocking in 1% BSA for 1 hr. An mTOR
antibody (the same used in immunoblots) was added overnight at
4°C, followed by 3 washes in PBS and incubation with anti-rabbit
AlexaFluor 555 (Molecular Probes, Eugene, OR) for 30 min.
Sections were washed again three times in PBS and mounted in
Vectashield plus DAPI (Vector Labs, Burlingame, CA). Slides were
viewed under a Zeiss LSM510 confocal microscope (Carl Zeiss
MicroImaging Inc., Thornwood, NY). Negative controls consisted
of adsorption of the mTOR antibody with a blocking peptide
or skipping the primary antibody. The images shown were taken
1744

Figure 8. Proposed role of mTORC1 and 2 signaling in perpetuating a
hyperactive energy supply-and-demand cycle upon high-fat/high-cholesterol (HF/HC) diet feeding. The HF/HC diet induced several metabolic
changes (1), including hypercholesterolemia, slight hypertriglyceridemia,
slight hypertension (HTN), and, in some pigs, insulin resistance. The HF/
HC diet may have increased free fatty acid (FFA) availability and total
energy supply (2) to the myocardium. By affecting various upstream mediators, including Akt and AMPK, and increasing total mTOR and raptor
levels (3), the HF/HC diet activated both mTORC1 and mTORC2 in myocytes. Myocardial energy demand was enhanced by mTORC1 (4), which
promotes translation, the synthesis of contractile proteins, and enhances
contractility. mTORC1 also inhibited autophagy (5), potentially leading
to the accumulation of misfolded proteins, mitochondrial dysfunction, and
premature myocardial senescence. mTORC2 potentiated this cycle by
activating Akt, which transports more nutrients into the myocardium and
further activates mTORC1. These metabolic and signaling alterations
induced by the HF/HC diet may increase the susceptibility of myocytes to
ischemia-reperfusion (I/R) injury.

at settings for which incubation with secondary antibody alone
showed no signal.
Antibodies. All antibodies and blocking peptide were obtained
from Cell Signaling Technology (Beverly, MA) with the following
exceptions: anti-α-tubulin and anti-HIF-1α from Sigma (St. Louis,
MO), anti-REDD1 from Proteintech Group, Inc. (Chicago, IL),
anti-PKCα and anti-β-actin HRP from Santa Cruz Biotechnology
(Santa Cruz, CA), anti-troponin I and anti-troponin T from
US Biologicals (Swampscott, MA), and peroxidase-conjugated
anti-rabbit light-chain specific secondary antibody from Jackson
Immunoresearch (West Grove, PA) for phospho-S6K1 blots. The
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phospho-pan PKC antibody was #9371 from Cell Signaling.
Statistical analysis. Densitometry values were analyzed with
the unpaired student’s t-test or Mann-Whitney U test when
appropriate (SigmaStat, Systat Software, San Jose, CA), and Pearson
or Spearman’s correlation coefficients with respective p values were
calculated using GraphPad Prism 4 (GraphPad Software, La Jolla,
CA). One control animal was excluded from the study using
Dixon’s Q-test due to extremely high phosphorylation and total
levels of many proteins measured in this study.
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